Medtronic Veteran Rob ten Hoedt Appointed Chairman of Coramaze Technologies Ahead of IPO

Coramaze Technologies Announces Appointment of Former Medtronic Executive Rob ten Hoedt as Chairman of the Board.Rob ten Hoedt has taken on the role of chairman of a medical technology company for the second time since retiring from Medtronic last year. He has already agreed to become the chairman of Onward, a developer of spinal cord stimulation technology, by the end of 2024.

Rob ten Hoedt Resume

Rob ten Hoedt is a 30-year veteran of Medtronic, having served as Executive Vice President and President of Global Regions before his retirement. He initially joined Medtronic in 1991 as the Market Manager for the Neuro business in Western Europe.

Coramaze Technologies is an innovative medical device company headquartered in Germany, dedicated to developing the Tripair minimally invasive transcatheter solution for structural heart disease. This innovative tricuspid valve repair solution aims to improve the quality of life for patients with tricuspid regurgitation (TR). Tripair achieves this throughAgainstFlowFilling RepairRecovery TechnologySimplifying the TR treatment process has the potential to reduce surgical complexity and improve treatment accessibility.

Evaluation of Coramaze Technologies

"We are delighted to welcome Rob as the Chairman of the Board. This appointment marksAn important milestone for Coramaze Technologies, further demonstrating the potential of Tripair as a disruptive therapy for tricuspid regurgitation. We will work together to deliver meaningful innovation and improve the quality of life for patients worldwide.

---Jochen Reinöhl  Coramaze TechnologiesChief Executive Officer

Rob ten Hoedt's Statement

"I am very honored inJoining Coramaze Technologies at a critical stage of development, Tripair is a revolutionary technology that greatly simplifies the treatment of tricuspid regurgitation by overcoming barriers of complexity, cost, and application. Its streamlined treatment approach significantly improves the accessibility of effective treatment, enabling physicians to help more patients who currently lack suitable treatment options. I look forward to working withCoramaze Technologies team joins hands to ultimately bring this solution to patients and medical institutions worldwide."